航空航天医学杂志
航空航天醫學雜誌
항공항천의학잡지
AEROSPACE MEDICINE
2014年
8期
1063-1065
,共3页
周殷%高振军%孙久滨%张莉%夏立志%郭桂玲
週慇%高振軍%孫久濱%張莉%夏立誌%郭桂玲
주은%고진군%손구빈%장리%하립지%곽계령
冠心病%体外反搏%PGI2%t-PA%TXB2%AngⅡ
冠心病%體外反搏%PGI2%t-PA%TXB2%AngⅡ
관심병%체외반박%PGI2%t-PA%TXB2%AngⅡ
Coronary heart disease%External counterpulsation%PGI2%t-PA%TXB2%AngⅡ
目的:观察新型体外反搏(EECP)对冠心病患者血清前列环素(Prostacyclin PGI2),组织型纤溶酶原激活物(t-PA),血栓素B2(TXB2),血管紧张素Ⅱ(angio tensin Ⅱ,AngⅡ)的影响,探讨EECP治疗冠心病的机制。方法收集100例冠心病患者(体外反搏组52例,单纯药物组48例)治疗前后外周静脉血清,两组均予常规药物治疗,体外反搏组每天给予60 min体外反搏,每周五次,二周为一疗程。采用酶联免疫吸附法( ELISA)检测测定各血清中PGI 2,t-PA ,TXB 2,AngⅡ的水平,并进行各组分析比较PGI 2,t-PA ,TXB2,AngⅡ的水平。结果经过单纯2周药物治疗和联合新型体外反搏治疗后,较治疗前相比,冠心病患者外周血清中PGI2, t -PA , TXB2,AngⅡ水平:在体外反搏组TXB2,AngⅡ含量明显降低(P<0.05),PGI2,t-PA含量明显升高(P<0.05);而在药物治疗组, PGI2,t-PA ,TXB2,AngⅡ含量虽有变化,但均无明显变化( P>0.05)。结论冠心病患者呈血管内皮功能失调,纤溶系统功能降低。新型体外反搏可降低TXB2,AngⅡ的产生,并促进PGI2,t-PA的释放,减轻脂质过氧化反应,稳定易损斑块,对血管内皮有保护作用,这是新型体外反搏为临床上治疗冠心病的提供了新途径。
目的:觀察新型體外反搏(EECP)對冠心病患者血清前列環素(Prostacyclin PGI2),組織型纖溶酶原激活物(t-PA),血栓素B2(TXB2),血管緊張素Ⅱ(angio tensin Ⅱ,AngⅡ)的影響,探討EECP治療冠心病的機製。方法收集100例冠心病患者(體外反搏組52例,單純藥物組48例)治療前後外週靜脈血清,兩組均予常規藥物治療,體外反搏組每天給予60 min體外反搏,每週五次,二週為一療程。採用酶聯免疫吸附法( ELISA)檢測測定各血清中PGI 2,t-PA ,TXB 2,AngⅡ的水平,併進行各組分析比較PGI 2,t-PA ,TXB2,AngⅡ的水平。結果經過單純2週藥物治療和聯閤新型體外反搏治療後,較治療前相比,冠心病患者外週血清中PGI2, t -PA , TXB2,AngⅡ水平:在體外反搏組TXB2,AngⅡ含量明顯降低(P<0.05),PGI2,t-PA含量明顯升高(P<0.05);而在藥物治療組, PGI2,t-PA ,TXB2,AngⅡ含量雖有變化,但均無明顯變化( P>0.05)。結論冠心病患者呈血管內皮功能失調,纖溶繫統功能降低。新型體外反搏可降低TXB2,AngⅡ的產生,併促進PGI2,t-PA的釋放,減輕脂質過氧化反應,穩定易損斑塊,對血管內皮有保護作用,這是新型體外反搏為臨床上治療冠心病的提供瞭新途徑。
목적:관찰신형체외반박(EECP)대관심병환자혈청전렬배소(Prostacyclin PGI2),조직형섬용매원격활물(t-PA),혈전소B2(TXB2),혈관긴장소Ⅱ(angio tensin Ⅱ,AngⅡ)적영향,탐토EECP치료관심병적궤제。방법수집100례관심병환자(체외반박조52례,단순약물조48례)치료전후외주정맥혈청,량조균여상규약물치료,체외반박조매천급여60 min체외반박,매주오차,이주위일료정。채용매련면역흡부법( ELISA)검측측정각혈청중PGI 2,t-PA ,TXB 2,AngⅡ적수평,병진행각조분석비교PGI 2,t-PA ,TXB2,AngⅡ적수평。결과경과단순2주약물치료화연합신형체외반박치료후,교치료전상비,관심병환자외주혈청중PGI2, t -PA , TXB2,AngⅡ수평:재체외반박조TXB2,AngⅡ함량명현강저(P<0.05),PGI2,t-PA함량명현승고(P<0.05);이재약물치료조, PGI2,t-PA ,TXB2,AngⅡ함량수유변화,단균무명현변화( P>0.05)。결론관심병환자정혈관내피공능실조,섬용계통공능강저。신형체외반박가강저TXB2,AngⅡ적산생,병촉진PGI2,t-PA적석방,감경지질과양화반응,은정역손반괴,대혈관내피유보호작용,저시신형체외반박위림상상치료관심병적제공료신도경。
Objective To investigate the effect of enhanced external counterpulsation ( EECP) on serum PGI2、t-PA、TXB 2 and AngⅡin patients with coronary heart disease ( CHD) and its mechanism.Methods The serum PGI 2、t-PA、TXB 2 and AngⅡlevels of 100 cases of CHD were tested.Patients were divided into EECP group (52 cases) and medication group (48 cases).The serum concentrations of PGI 2、t-PA、TXB2 and AngⅡof each group before and after treatment were compared for the correlation analysis.Results After 2 weeks medication treatment or EECP treatment , compared withthe levels before treatment , the serum levels in CHD patients EECP group were as follows.PGI2 and t-PA increased significantly ( P<0.05 ) , TXB2 and AngⅡ decreased significantly ( P<0.05 ).Conclusions Coronary heart disease patients with vascular endothelial dysfunction , fibrinolytic function decreased.Enhanced external counter-pulsation can reduce the TXB 2 and AngⅡproduction , and promote the release of PGI 2 and t-PA, reduce lipid peroxi-dation, stabilizing the vulnerable plaque , and has a protective effect on endothelial cells , which may be one of the mech-anisms of enhanced external counterpulsation therapy of coronary heart disease in clinic .